FDA and Biogen's push to accelerate approval of Alzheimer's drug

A new report by STAT is shedding light on the FDA's recent approval of the controversial Alzheimer's drug Aduhelm. Reporter Damian Garde joined CBSN to discuss what his investigation uncovered.